BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 11802813)

  • 1. O(6)-methylguanine-DNA methyltransferase (MGMT) as a determinant of resistance to camptothecin derivatives.
    Okamoto R; Takano H; Okamura T; Park JS; Tanimoto K; Sekikawa T; Yamamoto W; Sparreboom A; Verweij J; Nishiyama M
    Jpn J Cancer Res; 2002 Jan; 93(1):93-102. PubMed ID: 11802813
    [TBL] [Abstract][Full Text] [Related]  

  • 2. DNA repair enzyme, O6-methylguanine DNA methyltransferase, modulates cytotoxicity of camptothecin-derived topoisomerase I inhibitors.
    Kuo CC; Liu JF; Chang JY
    J Pharmacol Exp Ther; 2006 Feb; 316(2):946-54. PubMed ID: 16258022
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Growth inhibitory effect of a new camptothecin analog, DX-8951f, on various drug-resistant sublines including BCRP-mediated camptothecin derivative-resistant variants derived from the human lung cancer cell line PC-6.
    Ishii M; Iwahana M; Mitsui I; Minami M; Imagawa S; Tohgo A; Ejima A
    Anticancer Drugs; 2000 Jun; 11(5):353-62. PubMed ID: 10912951
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Unique action determinants of double acting topoisomerase inhibitor, TAS-103.
    Okamoto R; Takano H; Sekikawa T; Tanaka T; Toyada M; Ukon K; Tanimoto K; Kumazaki T; Nishiyama M
    Int J Oncol; 2001 Nov; 19(5):921-7. PubMed ID: 11604989
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Transcriptional repression of O6-methylguanine DNA methyltransferase gene rendering cells hypersensitive to N,N'-bis(2-chloroethyl)-N-nitrosurea in camptothecin-resistant cells.
    Ma LC; Kuo CC; Liu JF; Chen LT; Chang JY
    Mol Pharmacol; 2008 Aug; 74(2):517-26. PubMed ID: 18492797
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Determinants of drug response in camptothecin-11-resistant glioma cell lines.
    Matsumoto Y; Fujiwara T; Nagao S
    J Neurooncol; 1995; 23(1):1-8. PubMed ID: 7623066
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterization of a human small-cell lung cancer cell line resistant to a new water-soluble camptothecin derivative, DX-8951f.
    Nomoto T; Nishio K; Ishida T; Mori M; Saijo N
    Jpn J Cancer Res; 1998 Nov; 89(11):1179-86. PubMed ID: 9914787
    [TBL] [Abstract][Full Text] [Related]  

  • 8. DX-8951f, a water-soluble camptothecin analog, exhibits potent antitumor activity against a human lung cancer cell line and its SN-38-resistant variant.
    Joto N; Ishii M; Minami M; Kuga H; Mitsui I; Tohgo A
    Int J Cancer; 1997 Aug; 72(4):680-6. PubMed ID: 9259410
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting methylguanine-DNA methyltransferase in the treatment of neuroblastoma.
    Wagner LM; McLendon RE; Yoon KJ; Weiss BD; Billups CA; Danks MK
    Clin Cancer Res; 2007 Sep; 13(18 Pt 1):5418-25. PubMed ID: 17875772
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Quantitative analysis of DNA topoisomerase I activity in human and rat glioma: characterization and mechanism of resistance to antitopoisomerase chemical, camptothecin-11.
    Matsumoto Y; Fujiwara T; Honjo Y; Sasaoka N; Tsuchida T; Nagao S
    J Surg Oncol; 1993 Jun; 53(2):97-103. PubMed ID: 8388965
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antitumor effect of DX-8951, a novel camptothecin analog, on human pancreatic tumor cells and their CPT-11-resistant variants cultured in vitro and xenografted into nude mice.
    Takiguchi S; Kumazawa E; Shimazoe T; Tohgo A; Kono A
    Jpn J Cancer Res; 1997 Aug; 88(8):760-9. PubMed ID: 9330608
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification and characterization of a deletion mutant of DNA topoisomerase I mRNA in a camptothecin-resistant subline of human colon carcinoma.
    Yanase K; Sugimoto Y; Tsukahara S; Oh-Hara T; Andoh T; Tsuruo T
    Jpn J Cancer Res; 2000 May; 91(5):551-9. PubMed ID: 10835501
    [TBL] [Abstract][Full Text] [Related]  

  • 13. p16INK4 expression is associated with the increased sensitivity of human non-small cell lung cancer cells to DNA topoisomerase I inhibitors.
    Fukuoka K; Adachi J; Nishio K; Arioka H; Kurokawa H; Fukumoto H; Ishida T; Nomoto T; Yokote H; Tomonari A; Narita N; Yokota J; Saijo N
    Jpn J Cancer Res; 1997 Oct; 88(10):1009-16. PubMed ID: 9414664
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sensitization of acnu killing effects on HeLa S3 cells by MGMT antisense RNA transfection.
    Ji S; You Y; Wu Y; Chen J; Yang J; Zhang Y
    Chin Med Sci J; 1998 Mar; 13(1):14-9. PubMed ID: 11717917
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of topoisomerase I catalytic activity as determinant of drug response in human cancer cell lines.
    Voigt W; Vanhoefer U; Yin MB; Minderman H; Schmoll HJ; Rustum YM
    Anticancer Res; 1997; 17(5A):3707-11. PubMed ID: 9413228
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Application of antisense ribonucleic acid complementary to O6-methylguanine-deoxyribonucleic acid methyltransferase messenger ribonucleic acid for therapy of malignant gliomas.
    Nagane M; Asai A; Shibui S; Nomura K; Kuchino Y
    Neurosurgery; 1997 Aug; 41(2):434-40; discussion 440-1. PubMed ID: 9257312
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Induction of p53-dependent and p53-independent cellular responses by topoisomerase 1 inhibitors.
    McDonald AC; Brown R
    Br J Cancer; 1998 Sep; 78(6):745-51. PubMed ID: 9743293
    [TBL] [Abstract][Full Text] [Related]  

  • 18. O6-methylguanine-DNA methyltransferase (MGMT) transfectants of a 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU)-sensitive colon cancer cell line selectively repopulate heterogenous MGMT+/MGMT- xenografts after BCNU and O6-benzylguanine plus BCNU.
    Phillips WP; Willson JK; Markowitz SD; Zborowska E; Zaidi NH; Liu L; Gordon NH; Gerson SL
    Cancer Res; 1997 Nov; 57(21):4817-23. PubMed ID: 9354444
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Enforced expression of wild-type p53 curtails the transcription of the O(6)-methylguanine-DNA methyltransferase gene in human tumor cells and enhances their sensitivity to alkylating agents.
    Srivenugopal KS; Shou J; Mullapudi SR; Lang FF; Rao JS; Ali-Osman F
    Clin Cancer Res; 2001 May; 7(5):1398-409. PubMed ID: 11350911
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Determinants of CPT-11 and SN-38 activities in human lung cancer cells.
    van Ark-Otte J; Kedde MA; van der Vijgh WJ; Dingemans AM; Jansen WJ; Pinedo HM; Boven E; Giaccone G
    Br J Cancer; 1998 Jun; 77(12):2171-6. PubMed ID: 9649129
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.